drugset / Trial / NCT02889900
Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer
Phase 2
Completed
62 enrolled
AstraZeneca
Merck Sharp & Dohme LLC · collabMyriad Genetic Laboratories, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, single arm, multi-center study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in platinum-resistant relapsed high grade serous, high grade endometroid or clear cell ovarian, fallopian tube or primary peritoneal carcinoma patients who have received at least 3 prior lines of chemotherapy and who do not carry deleterious or suspected deleterious germline breast cancer susceptibility gene (BRCA) mutations.
Timeline
- Start
- 2017-01-17
- Primary completion
- 2019-08-27
- Completion
- 2021-03-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | 30 mg | Oral |
| Subject | Olaparib | Small molecule | 200 mg | Oral |
Indications
No indication recorded.